Bayer Income from Discontinued Operations 2010-2024 | BAYRY
Bayer annual/quarterly income from discontinued operations history and growth rate from 2010 to 2024. Income from discontinued operations can be defined as income or loss from the complete discontinuation of a segment or business, net of associated taxes and fees.
- Bayer income from discontinued operations for the quarter ending September 30, 2024 was $M, a NAN% increase year-over-year.
- Bayer income from discontinued operations for the twelve months ending September 30, 2024 was $0M, a NAN% increase year-over-year.
- Bayer annual income from discontinued operations for 2023 was $0B, a NAN% decline from 2022.
- Bayer annual income from discontinued operations for 2022 was $0B, a NAN% decline from 2021.
- Bayer annual income from discontinued operations for 2021 was $0B, a 100% decline from 2020.
Bayer Annual Income from Discontinued Operations
(Millions of US $) |
| 2023 |
$ |
| 2022 |
$ |
| 2021 |
$ |
| 2020 |
$5,796 |
| 2019 |
$1,882 |
| 2018 |
$0 |
| 2017 |
$5,477 |
| 2016 |
$297 |
| 2015 |
$89 |
| 2014 |
$ |
| 2013 |
$ |
| 2012 |
$ |
| 2011 |
$0 |
| 2010 |
$0 |
| 2009 |
$0 |
Bayer Quarterly Income from Discontinued Operations
(Millions of US $) |
| 2024-09-30 |
|
| 2024-06-30 |
|
| 2024-03-31 |
|
| 2023-12-31 |
|
| 2023-09-30 |
|
| 2023-06-30 |
|
| 2023-03-31 |
|
| 2022-12-31 |
|
| 2022-09-30 |
|
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-12-31 |
|
| 2021-09-30 |
|
| 2021-06-30 |
$-8 |
| 2021-03-31 |
|
| 2020-12-31 |
$-210 |
| 2020-09-30 |
$5,796 |
| 2020-06-30 |
$78 |
| 2020-03-31 |
$132 |
| 2019-12-31 |
$1,836 |
| 2019-09-30 |
$46 |
| 2019-06-30 |
|
| 2019-03-31 |
$0 |
| 2018-12-31 |
$-0 |
| 2018-09-30 |
|
| 2018-06-30 |
$-10 |
| 2018-03-31 |
$10 |
| 2017-12-31 |
$1,238 |
| 2017-09-30 |
$4,023 |
| 2017-06-30 |
$163 |
| 2017-03-31 |
$53 |
| 2016-12-31 |
$109 |
| 2016-09-30 |
$83 |
| 2016-06-30 |
$62 |
| 2016-03-31 |
$43 |
| 2015-12-31 |
$52 |
| 2015-09-30 |
$18 |
| 2015-06-30 |
$19 |
| 2015-03-31 |
|
| 2014-12-31 |
|
| 2014-09-30 |
|
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-12-31 |
|
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2013-03-31 |
|
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
$0 |
| 2011-09-30 |
$0 |
| 2011-06-30 |
$0 |
| 2011-03-31 |
$0 |
| 2010-12-31 |
$0 |
| 2010-09-30 |
$0 |
| 2010-06-30 |
$0 |
| 2010-03-31 |
$0 |
| 2009-12-31 |
$0 |
| 2009-09-30 |
$0 |
| 2009-06-30 |
$0 |
| 2009-03-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$20.120B |
$51.553B |
|
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
|
